Focal Seals its Fate
Investors in biomedical stocks are a tough crowd. They want to see current revenue streams and a pipeline of large-market products. Unfortunately, surgical sealant developer Focal Inc. provided neither to a sufficient degree. In early May, Focal agreed to merge into Genzyme Biosurgery in a stock swap transaction. The modest purchase price of $12 million bears witness to the fact that Focal simply did not do a good job of making the transition from a technology developer to a product manufacturer, at least not in the timeframe of investors.
You may also be interested in...
Surgical sealants have promise, but can a host of companies convince surgeons that these adjunctive therapies are "need to have" not "nice to have" technologies?
New data seems to indicate an uptick in the percentage of premarket applications that receive a major deficiency letter. See what US FDA spokesperson Alison Hunt said about strategies to avoid them.
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.